MedKoo Cat#: 565129 | Name: Intervenolin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Intervenolin is a natural potent inhibitor of H. pylori DHODH which has greater efficacy for treatment of H. pylori infection.

Chemical Structure

Intervenolin
Intervenolin
CAS#NONE

Theoretical Analysis

MedKoo Cat#: 565129

Name: Intervenolin

CAS#: NONE

Chemical Formula: C24H32N2OS2

Exact Mass: 428.1956

Molecular Weight: 428.65

Elemental Analysis: C, 67.25; H, 7.52; N, 6.54; O, 3.73; S, 14.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Intervenolin
IUPAC/Chemical Name
1-[[Bis(methylsulfanyl)methylideneamino]methyl]-2-[(2E)-3,7-dimethylocta-2,6-dienyl]-3-methylquinolin-4-one
InChi Key
IOISSMFNVJUMMP-NBVRZTHBSA-N
InChi Code
InChI=1S/C24H32N2OS2/c1-17(2)10-9-11-18(3)14-15-21-19(4)23(27)20-12-7-8-13-22(20)26(21)16-25-24(28-5)29-6/h7-8,10,12-14H,9,11,15-16H2,1-6H3/b18-14+
SMILES Code
O=C1C(C)=C(C/C=C(C)/CC/C=C(C)\C)N(C/N=C(SC)/SC)C2=C1C=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 428.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yoshida J, Abe H, Watanabe T, Kawada M. Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells. Oncol Lett. 2018 Nov;16(5):6777-6785. doi: 10.3892/ol.2018.9485. Epub 2018 Sep 21. PubMed PMID: 30405822; PubMed Central PMCID: PMC6202497. 2: Ohishi T, Masuda T, Abe H, Hayashi C, Adachi H, Ohba SI, Igarashi M, Watanabe T, Mimuro H, Amalia E, Inaoka DK, Mochizuki K, Kita K, Shibasaki M, Kawada M. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection. Helicobacter. 2018 Apr;23(2):e12470. doi: 10.1111/hel.12470. Epub 2018 Feb 28. PubMed PMID: 29488678. 3: Abe H, Kawada M, Igarashi M, Ohba SI, Hayashi C, Sakashita C, Watanabe T, Shibasaki M. Biological activity of intervenolin analogs with a phenyl substituent. J Antibiot (Tokyo). 2017 Oct 11. doi: 10.1038/ja.2017.123. [Epub ahead of print] PubMed PMID: 29018268. 4: Kawada M, Inoue H, Ohba S, Hatano M, Amemiya M, Hayashi C, Usami I, Abe H, Watanabe T, Kinoshita N, Igarashi M, Masuda T, Ikeda D, Nomoto A. Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2. J Antibiot (Tokyo). 2013 Sep;66(9):543-8. doi: 10.1038/ja.2013.42. Epub 2013 May 1. PubMed PMID: 23632919. 5: Abe H, Kawada M, Inoue H, Ohba S, Nomoto A, Watanabe T, Shibasaki M. Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents. Org Lett. 2013 May 3;15(9):2124-7. doi: 10.1021/ol400587a. Epub 2013 Apr 17. PubMed PMID: 23594173.